Effect of CYP2D6*10 allele on the pharmacokinetics of loratadine in Chinese subjects

Drug Metabolism and Disposition

Volumn 33, Issue 9, 2005, Pages 1283-1287

  Yin, Ophelia Q P ^a   Shi, X J ^b   Tomlinson, B ^a   Chow, Moses S S ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DESLORATADINE; LORATADINE; ANTIALLERGIC AGENT; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ADULT; ALLELE; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVATION; GENE; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; ASIAN; BLOOD; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS;

ADULT; ALLELES; ANTI-ALLERGIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; GENOTYPE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; POLYMORPHISM, GENETIC;

EID: 23944527343     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.005025     Document Type: Article

References (34)

1. Alvan G, Bechtel P, Iselius L, and Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39:533-537.
2. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, and Sjoqvist F (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51:388-397.
3. Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin CC, Cayen MN, and Affrime MB (1995) Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmcaol Ther 58:269-278.
4. Carr RA, Edmonds A, Shi H, Locke CS, Gustavson LE, Craft JC, Harris SI, and Palmer R (1998) Steady-state pharmacokinetics and electrocardiographic pharmcodynamics of clarithromycin and loratadine after individual or concomitant administration. Antimicrob Agents Chemother 42:1176-1180.
5. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F, and Bertilsson L (1995) Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 5:159-164.
6. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, and Goldstein JA (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825-831.
7. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, et al. (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-458.
8. Fang J, Baker GB, Silverstone PH, and Coutts RT (1997) Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 17:227-233.
9. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, and Leeder JS (1999) Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9:669-682.
10. Garcia-Barcelo M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL, and Waye MM (2000) Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem 46:18-23.
11. Geha RS and Meltzer EO (2001) Desloratadine: a new nonsedating oral antihistamine. J Allergy Clin Immunol 107:751-762.
12. Gibaldi M and Perrier D (1982). Pharmacokinetics, 2nd ed. Marcel Dekker, New York.
13. Gupta S, Banfield C, Kantesaria B, Flannery B, and Herron J (2004) Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J Clin Pharmacol 44:1252-1259.
14. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, and Huang JD (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29:268-273.
15. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, and Ingelman-Sundberg M (1994) Genetic analysis of the Chinese CYP2D6 locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459.
16. Katchen B, Cramer J, Chung M, Gural R, Hilbert J, Luc V, Mortizen V, D'Souza R, Symchowicz S, and Zampaglione N (1985) Disposition of 14C-SCH-29851 in humans. Ann Allergy 55:393.
17. Kosoglou T, Salfi M, Lim JM, Batra VK, Cayen MN, and Affrime MB (2000) Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. Br J Clin Pharmacol 50:581-589.
18. Matzke GR, Halstenson CE, Opsahl JA, Hilbert J, Perentesis G, Radwanski E, and Zampaglione N (1990) Pharmacokinetics of loratadine in patients with renal insufficiency. J Clin Pharmacol 30:364-371.
19. Mihara K, Suzuki A, Kondo T, Yasui N, Furukori H, Nagashima U, Otani K, Kaneko S, and Inoue Y (1999) Effect of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther 65:291-294.
20. Nakamura K, Goto F, Ray WA, Mcallister CB, Jacqz W, Wilkinson GR, and Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38:402-408.
21. Pan L and Belpaire FM (1999) In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol 55:599-604.
22. Radwanski E, Hilbert J, Symchowicz S, and Zampaglione N (1987) Loratadine: multiple-dose pharmacokinetics. J Clin Pharmacol 27:530-533.
23. Roh HK, Chung JY, Oh DY, Park CS, Svensson JO, Dahl ML, and Bertilsson L (2001) Plasma concentrations of haloperidol are related to CYP2D6 genotype at low but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 52:265-271.
24. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, and Gonzalez FJ (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56.
25. Sohn DR, Shin SG, Park CW, Kusaka M, Chiba K, and Ishizaki T (1991) Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 32:504-507.
26. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idre JR, and Gulbrandsen AK (1995) Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5:215-223.
27. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, and Kobayashi S (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 65:570-575.
28. ven Schaik RH, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, and Lindemans J (2001) The CYP3A4*3 allele: is it really rare? Clin Chem 47:1104-1106.
29. Walker AH, Jaffe JM, Gunasegaram S, Cummings SA, Huang CS, Chern HD, Olopade OI, Weber BL, and Rebbeck TR (1998) Characterization of an allelic variant in the nifedipinespecific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Hum Mutat 12:289.
30. Wang EJ, Casciano CN, Clement RP, and Johnson WW (2001) Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos 29:1080-1083.
31. Wang SL, Huang JD, Lai MD, Liu BH, and Lai ML (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410-418.
32. Yin OQ, Shi XJ, and Chow MS (2003) Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma. J Chromatogr 796:165-172.
33. Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, and Cayen MN (1996) Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 51:165-172.
34. Zhang YF, Chen XY, Zhong DF, and Dong YM (2003) Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. Acta Pharmacol Sin 24:715-718.